All Biomarkers articles
-
NewsATRX mutations reprogram chromatin to drive glioma progression
Scientists at MD Anderson Cancer Center have revealed how ATRX mutations restructure chromatin and activate oncogenic developmental pathways in glioma, pointing towards novel therapeutic targets including the HOXA signalling axis.
-
ArticleDrug development has changed. Bioanalysis is changing with it
As drug developers pursue increasingly complex therapies, traditional bioanalytical approaches are being put to the test. How is the field adapting to meet these new demands?
-
NewsCopper drug Cu(ATSM) reduces Alzheimer’s proteins by 42 percent in preclinical study
A copper-delivering compound has demonstrated the ability to restore blood-brain barrier clearance mechanisms, reducing amyloid-beta accumulation by 42 percent and improving spatial learning by 44 percent in Alzheimer’s disease models, according to research published in ACS Chemical Neuroscience.
-
ReportContext is everything: how spatial biology is changing our understanding of disease
Studying individual cells has revolutionised biomedical research, but it doesn’t tell the whole story. Discover how spatial biology is revealing disease mechanisms with implications for biomarkers, immunotherapy and drug development.
-
NewsNotch2 enables breast cancer dormancy in protective bone marrow niches
New research has demonstrated how breast cancer cells exploit protective bone marrow niches to remain dormant for years, identifying Notch2 signalling and stem cell-like markers as key regulators of cellular dormancy that could inform therapeutic strategies to prevent relapse.
-
NewsGene-based CIN score predicts breast cancer survival and immunotherapy response
A 13-gene chromosomal instability scoring system developed by Shanghai researchers correlates with survival outcomes and immunotherapy response in breast cancer patients.
-
ArticleMachine learning identifies biological signals linked to emotional hunger
Researchers at Phenomix Sciences are using machine learning and genetic risk scoring to investigate emotional hunger, an obesity phenotype linked to emotional and reward-driven eating behaviours. Dr Timothy O’Connor discusses how the approach could improve patient stratification, obesity research and treatment selection.
-
ArticleBeyond tangles: why soluble intracellular tau should guide drug discovery
Tau tangles are a hallmark of Alzheimer’s disease and related disorders, but evidence suggests the real damage may come from rare, soluble tau species inside neurons. Targeting these hidden drivers of circuit dysfunction could be key to restoring memory and cognition.
-
ArticleWhy AI models need patient data to deliver in drug discovery
Despite rapid advances in AI, many drug discovery models still struggle to translate computational predictions into clinical outcomes. Thomas Clozel explains how Owkin is training AI on large-scale patient-derived data while integrating experimental and clinical validation directly into model development.
-
NewsPERM1 protein linked to heart recovery in LVAD patients
A newly identified protein may explain why some failing hearts recover function following mechanical support while others do not.
-
ArticleAACR 2026 part one: AI design, precision biology and the next wave of oncology innovation
At AACR 2026, industry leaders discussed how oncology R&D is moving beyond isolated technological advances towards integrated discovery systems.
-
NewsCD4+ T cells identified as key to hepatitis B clearance
University of California, San Francisco researchers have identified a crucial immune mechanism involving CD4+ T cells that explains why some chronic hepatitis B patients successfully clear the virus after stopping antiviral treatment.
-
NewsYAP1 protein found to drive chemotherapy resistance in small cell lung cancer after treatment
University of Texas MD Anderson Cancer Center researchers have discovered that YAP1 protein expression emerges after chemotherapy treatment in small cell lung cancer, enabling resistant cancer cells to survive and proliferate.
-
NewsMachine learning identifies five distinct Parkinson’s disease subtypes
A new study from VIB and KU Leuven has revealed that Parkinson’s disease comprises five distinct molecular subtypes, each requiring tailored therapeutic approaches.
-
NewsOsteoporosis drugs may slow progression of aortic aneurysms
Researchers at Nagoya University have identified clonal haematopoiesis as a driver of aortic aneurysm progression and demonstrated that FDA-approved osteoporosis therapies targeting the RANK/RANKL pathway can significantly slow disease progression in preclinical models.
-
NewsChampions Oncology to present eight studies at AACR 2026
Champions Oncology will present eight studies at AACR 2026 spanning KRAS-mutant tumours, ovarian cancer, glioblastoma and emerging therapies including radiopharmaceuticals and CAR-T, using patient-derived models to improve early-stage decision-making in oncology drug development.
-
NewsZebrafish drug screening identifies precision therapies for autism
Yale University researchers have created a behavioural drug screening database using zebrafish models to identify FDA-approved compounds that reverse disrupted behaviours linked to autism risk genes.
-
ArticleImproving selectivity in antibody–drug conjugates
Promatix Biosciences is developing a new generation of bispecific antibody–drug conjugates using proprietary membrane proteomics data to identify highly selective target pairings. CEO Dr Michael Hunter explains how the company’s TXPro database enables discovery of previously unexplored tumour biology to improve therapeutic index and reduce on-target/off-tumour toxicities in solid tumours.
-
WebinarManufacturing the Future: from N=1 personalised CRISPR therapy to scalable precision genomic medicine
How biotech leaders are turning one-off CRISPR breakthroughs into scalable, regulatory-ready therapies.
-
NewsDNA-based system delivers targeted cancer drugs via biomarker logic
Researchers at the University of Geneva have developed a DNA-based drug delivery platform that uses molecular logic gates to identify cancer cells through dual biomarker recognition. The system activates cytotoxic agents only when both tumour markers are present, offering enhanced specificity over current antibody–drug conjugates while enabling deeper tissue penetration and multi-drug combinations.